Literature DB >> 18505684

Association between enzymatic and non-enzymatic antioxidant defense mechanism with apolipoprotein E genotypes in Alzheimer disease.

Hadi Kharrazi1, Asad Vaisi-Raygani, Zohreh Rahimi, Haidar Tavilani, Mahdi Aminian, Tayebeh Pourmotabbed.   

Abstract

OBJECTIVE: There are evidence suggesting that APOE-varepsilon4 allele play an important role in the pathogenesis of Alzheimer's disease (AD) by reducing peripheral levels and activities of a broad spectrum of nonenzymatic and enzymatic antioxidants systems. However, the link between APOE genotype, oxidative stress, and AD has yet to be established. In this study we examined whether antioxidant defense mechanism exacerbates the risk of AD in individual carrying APOE-varepsilon4 allele in a population from Tehran, Iran.
METHOD: We determined the enzymatic activities of the erythrocyte Cu-Zn superoxide dismutase (Cu-Zn SOD), glutathione peroxidase (GSH-Px), catalase (CAT) and serum level of total antioxidant status(TAS) in various APOE genotypes in 91 patients with AD and 91 healthy subjects as control group (age and sex-matched). RESULT: The results showed that the TAS level and the activities of enzymatic antioxidants CAT and GSH-Px were significantly lower and the SOD activity was significantly higher in AD patients compared to controls. The AD patients with APOE-varepsilon4 allele genotype had significantly lower serum TAS concentration and lower erythrocytes GSH-Px and CAT activities (p=0.001) but significantly higher erythrocytes Cu-Zn SOD activity (p=0.001) than the non-APOE-varepsilon4 carrier AD and the control group. In addition, the association observed between the factors involved in an antioxidant defense mechanism and APOE-varepsilon4 allele in AD increased with age of the subjects.
CONCLUSION: These data indicate that the reduced serum level of TAS and activity of CAT, GSH-Px and increased SOD exacerbate the risk of AD in individuals carrying APOE-varepsilon4 allele. The reduced antioxidants defense in APOE-varepsilon4 allele carrier may contribute to beta-amyloidosis. This effect, however, is more pronounced in the AD patients older than 75 years of age. This suggests that a therapeutic modality should be considered for these subjects.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18505684     DOI: 10.1016/j.clinbiochem.2008.05.001

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  20 in total

1.  Age-related defects in erythrocyte 2,3-diphosphoglycerate metabolism in dementia.

Authors:  Yury G Kaminsky; V Prakash Reddy; Ghulam Md Ashraf; Ausaf Ahmad; Valery V Benberin; Elena A Kosenko; Gjumrakch Aliev
Journal:  Aging Dis       Date:  2013-10-01       Impact factor: 6.745

Review 2.  Dietary omega 3 polyunsaturated fatty acids and Alzheimer's disease: interaction with apolipoprotein E genotype.

Authors:  P Barberger-Gateau; C Samieri; C Féart; M Plourde
Journal:  Curr Alzheimer Res       Date:  2011-08       Impact factor: 3.498

3.  Cyclic O3 exposure synergizes with aging leading to memory impairment in male APOE ε3, but not APOE ε4, targeted replacement mice.

Authors:  Chunsun Jiang; Luke T Stewart; Hui-Chien Kuo; William McGilberry; Stephanie B Wall; Bill Liang; Thomas van Groen; Shannon M Bailey; Young-Il Kim; Trent E Tipple; Dean P Jones; Lori L McMahon; Rui-Ming Liu
Journal:  Neurobiol Aging       Date:  2019-05-17       Impact factor: 4.673

4.  Neuroprotective effects of nootkatone from Alpiniae oxyphyllae Fructus against amyloid-β-induced cognitive impairment.

Authors:  Bosai He; Fanxing Xu; Feng Xiao; Tingxu Yan; Bo Wu; Kaishun Bi; Ying Jia
Journal:  Metab Brain Dis       Date:  2017-11-24       Impact factor: 3.584

5.  Astrocytic redox remodeling by amyloid beta peptide.

Authors:  Sanjay K Garg; Victor Vitvitsky; Roger Albin; Ruma Banerjee
Journal:  Antioxid Redox Signal       Date:  2011-03-28       Impact factor: 8.401

6.  Antioxidant effect of dietary supplement Withania somnifera L. reduce blood glucose levels in alloxan-induced diabetic rats.

Authors:  Rajangam Udayakumar; Sampath Kasthurirengan; Ayyappan Vasudevan; Thankaraj Salammal Mariashibu; Jesudass Joseph Sahaya Rayan; Chang Won Choi; Andy Ganapathi; Sei Chang Kim
Journal:  Plant Foods Hum Nutr       Date:  2010-06       Impact factor: 3.921

7.  A Scoping Review of Dietary Factors Conferring Risk or Protection for Cognitive Decline in APOE ε4 Carriers.

Authors:  G M Fote; N R Geller; A M Reyes-Ortiz; L M Thompson; J S Steffan; J D Grill
Journal:  J Nutr Health Aging       Date:  2021       Impact factor: 4.075

8.  Antioxidant status and APOE genotype as susceptibility factors for neurodegeneration in Alzheimer's disease and vascular dementia.

Authors:  Giancarlo Zito; Renato Polimanti; Valentina Panetta; Mariacarla Ventriglia; Carlo Salustri; Maria Cristina Siotto; Filomena Moffa; Claudia Altamura; Fabrizio Vernieri; Domenico Lupoi; Emanuele Cassetta; Paolo M Rossini; Rosanna Squitti
Journal:  Rejuvenation Res       Date:  2013-02       Impact factor: 4.663

9.  Benzothiazole aniline tetra(ethylene glycol) and 3-amino-1,2,4-triazole inhibit neuroprotection against amyloid peptides by catalase overexpression in vitro.

Authors:  Amrutha Chilumuri; Mark Odell; Nathaniel G N Milton
Journal:  ACS Chem Neurosci       Date:  2013-09-09       Impact factor: 4.418

10.  Late-onset Alzheimer's disease is associated with inherent changes in bioenergetics profiles.

Authors:  Kai-C Sonntag; Woo-In Ryu; Kristopher M Amirault; Ryan A Healy; Arthur J Siegel; Donna L McPhie; Brent Forester; Bruce M Cohen
Journal:  Sci Rep       Date:  2017-10-25       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.